Targetable Immune Biology Found in Some Patients With Early-Stage Prostate Cancer

Description

Although immunotherapy has improved outcomes across a growing number of cancers, its success in unselected cases of prostate cancer has been limited. According to data presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium, however, investigators have identified a group of patients with early-stage prostate cancer who may represent a viable target for immune checkpoint and DNA-damaging therapies.1Analysis of of two separate gene-expression assays has shown this subgroup of patients to be at increased risk of developing metastatic disease, but it has targetable immune biology.